Soolantra is used in the management of inflammatory lesions of rosacea in adult patients. It is commonly used for the topical treatment of the papulopustular subtype. This is commonly used across conditions characterized by periods of heightened symptoms, specifically the facial eruptions of red bumps (papules) and pus-filled spots (pustules), which are the common indications.

Targeting Inflammatory Lesions and Symptom Burden

The treatment is relevant in clinical settings that involve active or disruptive symptom patterns. Beyond the management of visible lesions, the use of this cream provides support that helps ease the overall symptom burden. It is applied in scenarios where additional management of discomfort is required, helping to manage associated symptoms related to inflammatory or irritative states, such as stinging and burning sensations. This contributes to easing symptoms that interfere with daily functioning and assists with maintaining functional stability when symptoms are more noticeable.

“It provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.”

---

Quick Fact: Focus on Visible Lesions and Cutaneous Discomfort

---

Regulatory References

1. Australian Therapeutic Goods Administration Product Information

Eligibility Map: Who can and cannot use Soolantra — Official Regulatory Information

The eligibility to use Soolantra (ivermectin) cream 1% is strictly defined by government regulatory authorities based on established safety and efficacy data. This profile outlines the formal exclusions, limitations, and special considerations for patient populations.

Eligibility Status	Regulatory Requirement
Populations for whom use is allowed	Adult patients (ge 18 years) for the topical treatment of inflammatory lesions of rosacea.
Populations for whom use is contraindicated	Patients with known hypersensitivity (allergy) to the active substance (Ivermectin) or to any of the cream's excipients.
Age-related eligibility rules	Children and adolescents (< 18 years): Use is not recommended; safety and efficacy have not been established.
Pregnancy eligibility status	Not recommended during pregnancy. The potential benefit must justify the potential risk.
Lactation eligibility status	A decision must be made to discontinue breastfeeding or discontinue therapy, as a risk to the nursing child cannot be excluded.
Condition-specific eligibility rules	Severe hepatic impairment: Caution should be exercised during treatment.
	Renal impairment: Safety and efficacy have not been established in this patient group.

Interactions with other medicines and products

Soolantra (ivermectin) is a topical cream, and only minimal systemic absorption of the active ingredient, ivermectin, occurs when used as directed. As a result, the potential for drug-drug interactions with other medicines is considered low.

However, ivermectin is known to be primarily metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme in the liver. Although formal drug interaction studies have not been performed with Soolantra cream, caution is advised when it is used at the same time as potent inhibitors of the CYP3A4 enzyme.

Potential Pharmacokinetic Interaction

Concomitant administration with a potent CYP3A4 inhibitor could potentially lead to an increase in the plasma concentration (exposure) of ivermectin in the body. Despite the low absorption of the topical formulation, this interaction is theoretically possible and necessitates caution.

Other Interactions

• Other Topical Rosacea Treatments: The concurrent use of Soolantra with other topical or systemic medications intended to treat rosacea has not been investigated in clinical studies.
• Enzyme Effects: Laboratory (in vitro) studies have indicated that Soolantra cream, at therapeutic concentrations, is not expected to significantly inhibit or induce CYP450 enzymes.

Patients should always inform their healthcare provider about all prescription drugs, over-the-counter medicines, and herbal supplements they are currently using before starting treatment with Soolantra.

The mechanism of action for Ivermectin involves a dual pharmacodynamic action within the skin, focusing on microbial elimination and direct anti-inflammatory pathway modulation.

Targeted Modulation of Invertebrate Neurotransmission

This domain describes the molecule's antiparasitic activity. Ivermectin acts as a Positive Allosteric Modulator on Glutamate-gated Chloride Channels (GluCls), which are specific ion channels found only in the nerve and muscle cells of invertebrates like Demodex mites. This interaction causes a sustained influx of chloride ions, leading to the hyperpolarization of the mite's excitable cells. The resulting physiological effect is the paralysis and death of the mites, leading to a decrease in the microbial load on the skin.

️ Inhibition of Host Inflammatory Signaling

The second key domain involves the molecule's capacity for anti-inflammatory pathway modulation in human host tissue. Ivermectin engages and suppresses the Toll-like Receptor 4 (TLR4) signaling pathway on skin cells and resident immune cells. By blocking the activation of TLR4, the molecule interferes with the subsequent NF-kappaB cascade, which is the central mechanism for producing inflammatory mediators like certain cytokines and cathelicidin. This mechanism contributes to attenuation of the host's chronic inflammatory response in the skin, resulting in a physiological shift toward reduced pathway activity.

Instruction Map: How to use Soolantra — administration guidelines

---

Administration Scope

Feature	Guideline
Route of administration	Cutaneous use (Topical) only, specifically to the face. It is not approved for oral, ophthalmic, or intravaginal use.
Dosing schedule	Apply one small pea-size amount to each of the five facial areas: the forehead, chin, nose, and each cheek. The total daily amount is approximately 1 gram of the 1% cream.
Timing in relation to meals (if applicable)	Not applicable (topical medicine).
Preparation requirements (if applicable)	None required (ready-to-use cream).
Age-group administration rules	Approved for use in adult patients only (18 years of age and older). No dosage adjustment is explicitly necessary for the geriatric population.
Missed-dose rules	If a dose is missed, patients should return to the regular daily schedule. It is specifically stated not to use a double dose to make up for the forgotten application.
Special procedural conditions	Cosmetics may be applied only after the cream has dried. Hands must be washed immediately after application.

---

Instruction Classifications (High-Level)

Classification	Parameter
Administration method type	Topical / Cutaneous.
Frequency pattern	Once daily.
Use-context constraints	The standard course is up to four months of continuous application. If no improvement is observed after three months, the treatment should be discontinued.

---

Resulting procedural structure

Step sequence:

• Apply the cream to the affected facial areas, spreading a thin layer across the entire face.
• Ensure application strictly avoids contact with the eyes, lips, and other mucosal surfaces.
• Wash hands immediately and thoroughly following the application.

Connection to the overall use protocol (2–4 sentences): These instructions define the standardized application protocol, establishing the topical route and the fixed once-daily frequency. The regimen specifies the exact quantity measurement (pea-size amounts) and the maximum four-month initial duration for continuous use. This structure provides a clear framework for the product's administration and re-evaluation.

Soolantra: Recent Clinical Evidence

The efficacy and safety of Soolantra (ivermectin) cream, 1%, for the topical treatment of inflammatory lesions of rosacea were primarily evaluated across two identical Phase 3, 12-week, randomized, double-blind, vehicle-controlled clinical trials. These studies involved adult participants with moderate to severe papulopustular rosacea.

Clinical Efficacy Overview

Research examined the proportion of participants achieving treatment success, defined as an Investigator Global Assessment (IGA) score of 'clear' (0) or 'almost clear' (1), and the absolute reduction in inflammatory lesion count.

• Treatment Success: At the end of the 12-week trials, between 38.4% and 40.1% of participants treated with ivermectin cream achieved an IGA score of clear or almost clear, compared to 11.6% to 18.8% in the vehicle (placebo) groups.
• Lesion Reduction: The mean reduction in inflammatory lesion count from baseline was greater in the ivermectin group compared to the vehicle group in both trials.

Extended and Comparative Studies

Long-term extension studies, lasting an additional 40 weeks (totaling 52 weeks of treatment), were conducted to assess safety and sustained effect. These studies reported that the percentage of participants achieving IGA scores of clear or almost clear continued to increase up to week 52.

In a separate comparative trial, ivermectin cream was evaluated against metronidazole 0.75% cream, another topical rosacea treatment. This study reported a greater mean percentage reduction in inflammatory lesion count for the ivermectin group after 16 weeks of treatment.

Mechanism of Activity

The exact way ivermectin cream works in treating the inflammatory lesions of rosacea is not fully known. Studies suggest its activity may be linked to both anti-inflammatory effects and antiparasitic effects on Demodex mites, which are believed to be a contributing factor in the inflammation associated with rosacea.

Key Studies & References

1. Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea

Common questions about Soolantra (FAQ)

---

Q: How quickly does Soolantra start to show results for redness?

Official clinical studies indicate that some patients may notice an initial response within the first four weeks of starting treatment. However, the goal of treatment is to achieve the best outcome over the full course, with the full clinical effect generally assessed after 12 weeks of continuous use.

---

Q: Is it normal to experience a 'die-off' or initial worsening when starting Soolantra?

Regulatory documents acknowledge that a transient aggravation of rosacea can occur, which may involve a temporary increase in bumps or redness. This is an uncommon finding noted in clinical safety texts and is thought to be related to the medication’s effect on Demodex mites. This reaction has been observed to typically resolve with continued use of the cream.

---

Q: Is Soolantra safe to use long-term for chronic rosacea?

The approved course of treatment is up to four months, and clinical data from extension studies have assessed the safety and sustained effect for up to 52 weeks (one year). The safety and appropriateness of continued use beyond the studied period should be determined by a prescribing healthcare professional.

---

Q: Can Soolantra cause skin dryness or peeling?

Skin irritation and dry skin are reported as uncommon adverse reactions in the official product information. The official product information lists 'dry skin' as an uncommon adverse reaction. Other localized skin reactions are possible, as with any topical medication.

---

Q: Is sun sensitivity a common side effect while using Soolantra?

Sun sensitivity (photosensitivity) is not specifically listed as a common or uncommon side effect in regulatory documents. However, individuals with rosacea are generally aware that sunlight can be a common trigger for flare-ups.

---

Q: Does Soolantra interact with chemical sunscreens?

Official documentation advises that sunscreens and other cosmetics may be applied only after Soolantra cream has fully dried. Furthermore, the concurrent use of Soolantra with other topical products has not been specifically investigated in clinical studies.

---

Q: Does Soolantra help with the ocular (eye) symptoms of rosacea?

Soolantra cream is indicated only for the cutaneous treatment of inflammatory lesions of rosacea on the face. It is not approved for ophthalmic (eye) use, and direct contact with the eyes should be avoided during application.

---

Q: Can Soolantra be used on other areas of the body besides the face?

Official regulatory information states that the medicine is approved and indicated for use on the face only. It should be applied to the specific facial areas (forehead, chin, nose, and cheeks) and is not intended for use on other parts of the body.

---

Q: What's the difference between Soolantra and Metrogel (metronidazole cream)?

Soolantra contains ivermectin, which is an antiparasitic and anti-inflammatory agent, while Metrogel contains metronidazole, which is an antibiotic. Official comparative studies have reported a greater mean reduction in inflammatory lesion count for Soolantra compared to metronidazole cream over a 16-week period.

---

Q: Can Soolantra cause burning or stinging upon application?

A skin burning sensation is noted as the most commonly reported adverse reaction, affecting up to 1 in 10 people in clinical trials. This is generally a temporary, localized feeling on the skin.

---

Q: Is a prescription always required to get Soolantra?

Yes, Soolantra (ivermectin) cream, 1% is consistently classified as a prescription-only medicine in the countries where it has regulatory approval.

---

Q: Can Soolantra be applied at the same time as prescription retinoids or benzoyl peroxide?

Regulatory documents state that the concomitant use of Soolantra with other topical or systemic medications (including retinoids and benzoyl peroxide) has not been investigated in clinical studies. Caution is advised when considering any combination use.

---

Q: Does Soolantra treat acne as well as rosacea?

Soolantra is specifically indicated only for the treatment of inflammatory lesions of rosacea (papulopustular subtype) in adults. It is not approved for the treatment of acne vulgaris.

---

Q: Is Soolantra effective against all subtypes of rosacea?

The medicine is indicated for the treatment of inflammatory lesions of rosacea, which pertains to the papulopustular subtype. Its safety and efficacy have not been established or approved for treating other subtypes of rosacea.

---

Q: Is Soolantra absorbed systemically into the bloodstream?

Following proper topical application, regulatory data confirms there is a low systemic absorption of ivermectin. The concentration of the medicine found in the bloodstream is significantly lower than that observed with oral dosing.

---

Q: Is it normal for Soolantra to feel greasy or thick on the skin?

Soolantra is officially described as a white to pale yellow hydrophilic cream, which is an oil-in-water emulsion. Its texture is characteristic of this type of formulation designed for cutaneous application.

---

Q: Why is Soolantra sometimes prescribed when other rosacea treatments have failed?

Clinical studies have reported a greater mean reduction in inflammatory lesions for Soolantra compared to metronidazole 0.75% cream. This clinical finding of efficacy may influence prescribing decisions when a patient has not achieved satisfactory results with other first-line topical therapies.

---

Q: Can men and women use Soolantra equally effectively?

Clinical trials for Soolantra included both male and female adult participants. No clinically significant differences in effectiveness or safety were reported between male and female participants in the clinical trials.

---

Q: How long after starting Soolantra is the maximum effect usually reached?

Clinical trial data from extended studies reported that the proportion of participants achieving the highest success rating continued to increase over the treatment period, reaching its peak after up to 52 weeks of continuous extended use.

---

Q: Does using a thicker layer of Soolantra make it work better?

The official dosing instruction specifies applying a small, pea-size amount to each facial area and spreading it as a thin layer. Regulatory information does not support the idea that using a thicker application will enhance the medicine’s effectiveness.

---

Q: Can people with concurrent perioral dermatitis use Soolantra?

Soolantra is approved for rosacea, and official instructions strongly caution users to avoid application near the lips and mouth. The safety and effectiveness for treating concurrent perioral dermatitis have not been established.

---

Q: What is the mechanism by which ivermectin targets Demodex mites?

Studies suggest that Soolantra's activity is linked to both its antiparasitic action against Demodex mites and its anti-inflammatory effects in the skin. The exact way the medicine works in treating the inflammatory lesions of rosacea is not fully known.

---

Q: What percentage of people see an improvement in rosacea symptoms with Soolantra?

The primary clinical evidence focuses on the proportion of patients who achieved a high-level outcome (Investigator Global Assessment score of 'clear' or 'almost clear'), which was reported between 38.4% and 40.1% after 12 weeks. Mean reduction in inflammatory lesion count was also reported.

---

Q: Why do some people experience a temporary increase in bumps or pimples with Soolantra?

This initial temporary worsening is noted in safety documents as a 'transient aggravation of rosacea.' It is thought to be related to the medication’s action against Demodex mites and typically resolves with continued use.

Storage and Handling Requirements

Soolantra cream must be stored at controlled room temperature, specifically between 68 F to 77 F (20 C to 25 C). Brief temperature excursions are permitted up to 86 F (30 C). Official labeling requires that the product be stored away from excessive heat, moisture, and light, and it must not be frozen.

Storage Restriction	Requirement as Documented
Temperature	68 F to 77 F (20 C to 25 C)
Freezing/Refrigeration	Do not freeze
Container	Keep in a closed container
Stability	Use within 6 months after first opening

Child Safety and Disposal

The cream must be kept out of the sight and reach of children. Regarding disposal, unused or expired product must be discarded in accordance with local requirements and must not be thrown away via wastewater or general household waste, which protects against environmental contamination.